Grail Shares Drop After Mixed Results from NHS-Galleri Trial Presented at ASCO
Shares of Grail (NASDAQ: GRAL) fell by 16% following mixed results presented at the American Society of Clinical Oncology meeting. The Galleri test failed to meet its primary endpoint in reducing later-stage cancers but showed some positive outcomes, including a high episode sensitivity for certain deadly cancers.
Topics: biotech cancer_detection clinical_trials FDA_approval